This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cell & Gene Therapy Manufacturing & Commercialization US

Early Registration Savings Deadline Expires In

  • 00
  • 00
  • 00
  • 00
September 27-30, 2022
Boston Convention and Exhibition CenterBoston, MA

Gregg Nyberg
Chief Technology Officer at Landmark Bio


Gregg Nyberg, PhD

Gregg Nyberg is a biopharmaceutical executive with more than twenty years of experience in process development, clinical manufacturing, technology transfer and commercialization. He is currently Chief Technology Officer at Landmark Bio, where he is responsible for establishing process development and clinical manufacturing capabilities for emerging technologies such as cell and gene therapy.  Prior to joining Landmark, Gregg served in multiple leadership roles at Merck, Amgen and Wyeth BioPharma/Genetics Institute.  Most recently, Gregg was Head of Biologics Process Research & Development at Merck, where he was responsible for process development and clinical manufacturing of biologics drug substance.  Gregg received his Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.  

Agenda Sessions

  • Chairperson's Opening Remarks

  • Chairperson's Opening Remarks